Mount Sinai Tisch Cancer Institute
New York, New York, United States
Cancer treatment center in New York City, New York
1190 One Gustave L. Levy Place, New York, NY 10029
About Mount Sinai Tisch Cancer Institute
- Top Sponsors
- Top Collaborators
- Trials By Phase
- Recruitment Status
- Top Conditions
- Intervention Types
- Top Intervention Names
- Trials By Gender
Lead Sponsor
# Trials
Kite, A Gilead Company
1
Seagen Inc.
1
Clinical Trials at Mount Sinai Tisch Cancer Institute
During the past decade, Mount Sinai Tisch Cancer Institute conducted 2 clinical trials. In the 10-year time frame, 2 clinical trials started and 1 clinical trials were completed, i.e. on
average, 50% percent of trials that started reached the finish line to date. In the past 5 years, 1 clinical trials started and 1 clinical trials were completed. i.e. 100%
of trials that started reached the finish line.
Trials List
Trail ID
Brief Title
Start Date
Completion Date
Status
Enrollment
A Study Evaluating the Safety and Efficacy of Brexucabtagene Autoleucel (KTE-X19) in Adult Subjects With Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia (ZUMA-3)
2016-03-07
2034-11-01
Active, not recruiting
125
A Study of Disitamab Vedotin Alone and With Pembrolizumab in Urothelial Cancer That Expresses HER2
2022-05-03
2026-03-31
Recruiting
332
Clinical Trials Sponsors and Collaborators
In terms of collaborators to trials, out of the total clinical trials conducted in "Mount Sinai Tisch Cancer Institute"
#1 collaborator was "Merck Sharp & Dohme LLC" with 1 trials as a collaborator. Other collaborators include -1 different institutions and companies that were
collaborators in the rest 1 trials.
Clinical Trials Conditions at Mount Sinai Tisch Cancer Institute
According to Clinical.Site data, the most researched conditions in "Mount Sinai Tisch Cancer Institute" are
"Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia" (1 trials) and "Urothelial Carcinoma" (1 trials). Many other conditions were trialed in "Mount Sinai Tisch Cancer Institute" in a lesser frequency.
Clinical Trials Intervention Types at Mount Sinai Tisch Cancer Institute
Most popular intervention types in "Mount Sinai Tisch Cancer Institute" are "Drug" (2 trials) and "Biological" (1 trials). Other intervention types were less common.
The name of intervention was led by "Cyclophosphamide" (1 trials), "Fludarabine" (1 trials), "brexucabtagene autoleucel" (1 trials), "disitamab vedotin" (1 trials) and "pembrolizumab" (1 trials). Other intervention names were less common.
Clinical Trials Genders at Mount Sinai Tisch Cancer Institute
The vast majority of trials in "Mount Sinai Tisch Cancer Institute" are
2 trials for "All" genders.
Clinical Trials Status at Mount Sinai Tisch Cancer Institute
Currently, there are NaN active trials in "Mount Sinai Tisch Cancer Institute".
undefined are not yet recruiting,
1 are recruiting,
1 are Active, not recruiting,
and undefined are Enrolling by invitation.
In total, there were undefined completed trials in Mount Sinai Tisch Cancer Institute,
undefined suspended trials,
and undefined terminated clinical trials to date.
Out of the total trials that were conducted in Mount Sinai Tisch Cancer Institute, 1 "Phase 1"
clinical trials were conducted, 2 "Phase 2" clinical
trials and 0 "Phase 3" clinical trials were conducted as
well. "Phase 4" trials included 0 trials, and there were
also 0 trials that are defined as “Not Applicable".